BioStem Technologies Inc BSEM
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
BioStem Technologies to Host Third Quarter 2026 Financial Results Conference Call on November 12, 2026
BioStem Technologies’ CEO and COO Invest $1 Million in Cash Through Exercise of Stock Options
BioStem Technologies Strengthens Placental Allograft and Umbilical Tissue Patent Portfolio
BioStem Technologies Announces $3 Million Private Placement Priced At-The-Market Under Nasdaq Rules
BioStem Technologies Secures Up to $40 Million in a Committed Equity Facility
BioStem Technologies Opens Hospital Access for VENDAJE® and VENDAJE AC® Through Vizient and Premier
BioStem Technologies to Present at the H.C. Wainwright 28th Annual Global Investment Conference
Sidoti Events, LLC's August Micro-Cap Virtual Conference
Trading Information
- Previous Close Price
- $1.04
- Day Range
- $1.01–1.15
- 52-Week Range
- $1.01–7.64
- Bid/Ask
- $1.03 / $1.12
- Shares Outstanding
- 18.67M
- Market Cap
- $21.10M
- Volume/Avg
- 100,819 / 161,086
Key Statistics
- Price/Earnings (Normalized)
- 1.38
- Price/Sales
- 0.19
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
BioStem Technologies Inc is a regenerative biotechnology company focused on harnessing elements of perinatal tissue and the body's innate biology to repair or reverse damage caused by a broad range of degenerative diseases. The company develops, manufactures, and sells tissue allografts for the wound care market with a focus on the treatment of diabetic, pressure, and venous ulcers. Utilizing its proprietary BioRetain processing method, it manufactures perinatal tissue allografts. The company offers a comprehensive portfolio of high-quality brands that are trademarked and include VENDAJE AC, AmnioWrap2, and Others. The company generates key revenue from VENDAJE AC.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 2
Valuation
Metric | BSEM |
|---|---|
Price/Earnings (Normalized) | 1.38 |
Price/Book Value | 0.73 |
Price/Sales | 0.19 |
Price/Cash Flow | 1.07 |
Price/Earnings
BSEM
Financial Strength
Metric | BSEM |
|---|---|
Quick Ratio | 0.64 |
Current Ratio | 0.98 |
Interest Coverage | — |
Quick Ratio
BSEM
Profitability
Metric | BSEM |
|---|---|
Return on Assets (Normalized) | — |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | — |
Return on Assets
BSEM
Biotechnology Industry Comparables
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc VRTX | LOCK|$z%lbC | LOCK|<l##y | $139B | |||
| Moderna Inc MRNA | LOCK|%gF#j^ | LOCK|T>< | $103B | |||
| Regeneron Pharmaceuticals Inc REGN | LOCK|#tW?^^j | LOCK|^V?sk | $94B | |||
| argenx SE ADR ARGX | LOCK|Q&#VY< | LOCK|sgj | $58B | |||
| BeOne Medicines Ltd ADR ONC | LOCK|BHb$lS | LOCK|%m | $47B | |||
| Royalty Pharma PLC Class A RPRX | LOCK|&H^HPbL& | LOCK|CF?<v | $30B | |||
| Incyte Corp INCY | LOCK|LP?wt! | LOCK|D@ | $24B | |||
| BioNTech SE ADR BNTX | LOCK|rcnNcm | LOCK|Dx | $22B | |||
| Alnylam Pharmaceuticals Inc ALNY | LOCK|%FDPK& | LOCK|Dnbg | $21B | |||
| Jazz Pharmaceuticals PLC JAZZ | LOCK|KDq$lF# | LOCK|VW | $15B |
United States